查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842001

全球細胞和基因治療CDMO市場：市場規模、佔有率和趨勢分析（按階段、產品、適應症和地區分類），細分市場預測（2025-2033年）

Cell And Gene Therapy CDMO Market Size, Share & Trends Analysis Report By Phase, By Product, By Indication, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

細胞與基因治療CDMO市場摘要

全球細胞和基因治療 CDMO 市場預計到 2024 年將達到 43.1 億美元，到 2033 年將達到 271.2 億美元，2025 年至 2033 年的複合年成長率為 23.03%。

該行業的發展動力來自不斷擴大的細胞和基因治療產品組合、對罕見疾病日益成長的研究興趣，以及公共和私營部門對研發的大量投資。

其他推動成長的因素包括對細胞和基因治療外包服務日益成長的需求、癌症等慢性疾病的日益普遍、併購活動的激增以及細胞和基因治療開發過程中持續不斷的技術創新。市場成長的主要驅動力是生物技術和製藥業不斷增加的研發資金和對細胞和基因治療（CGT）療法的投資。細胞和基因療法在治療包括癌症、遺傳性疾病和某些感染疾病在內的多種疾病方面具有巨大潛力。因此，這些治療方法的巨大潛力激發了公共和私營部門對創新細胞和基因治療方法開發和發現的濃厚興趣。目前，大多數大型製藥公司都在投資CGT以建立強大的市場地位。創業投資，尤其是在生命科學領域的投資，已顯著增加。

此外，不斷成長的臨床研發管線以及對生產所需專業知識和基礎設施外包的持續依賴也是推動市場成長的因素。根據clinicaltrials.org網站發布的數據，目前有超過2000項正在進行的細胞和基因治療臨床試驗處於不同的研發階段，每項從早期到晚期的進展都會增加對病毒載體、質體和臨床級細胞處理的需求。 FDA在2023-2024年核准了Casgevy（用於治療鐮狀細胞貧血症）和Elevidys（用於治療Duchenne氏肌肉失養症）等新型療法，EMA也核准了Roctavian（用於治療A型血友病） ，這些都凸顯了先進療法進入商業化階段的強勁勢頭。大多數從事這些創新的中小型生物技術公司缺乏大規模的GMP設施，因此與CDMO（合約研發生產機構）合作對於惠及患者至關重要。為了因應這一成長，包括 Lonza、Catalent、無錫先進療法和賽默飛世爾科技在內的領先企業正大力投資擴大其病毒載體和細胞療法的生產能力，這表明它們對持續的外包需求充滿信心。隨著核准速度加快、研發管線不斷擴展以及生產需求超過企業內部產能，這些因素共同推動市場持續高速成長。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章：細胞與基因治療CDMO市場：促進因素、趨勢與範圍

  • 市場體系展望
  • 細胞與基因治療CDMO市場動態
  • 技術格局
  • 定價模式分析
  • 細胞與基因治療CDMO市場：分析工具

第4章：細胞和基因治療CDMO市場：按階段分類的估算和趨勢分析

  • 細分儀表板
  • 全球細胞與基因治療CDMO市場：趨勢分析及發展階段
  • 全球細胞基因治療CDMO市場規模及發展趨勢分析（依階段分類，2021-2033年）
  • 臨床前
  • 臨床

第5章：細胞和基因治療CDMO市場：按產品分類的估算和趨勢分析

  • 細分儀表板
  • 全球細胞和基因治療CDMO市場：波動分析（按產品分類）
  • 全球細胞基因治療CDMO市場規模及產品趨勢分析（2021-2033年）
  • 基因治療
    • 體外
    • 體內
  • 基因改造細胞療法
    • CAR-T細胞療法
    • CAR-NK細胞療法
    • TCR-T細胞療法
    • 其他
  • 細胞療法

第6章：細胞與基因治療CDMO市場：依適應症分類的估算與趨勢分析

  • 細分儀表板
  • 全球細胞和基因治療CDMO市場：按適應症分類的波動分析
  • 全球細胞及基因治療CDMO市場規模及趨勢分析（依適應症分類）（2021-2033年）
  • 瘤
  • 感染疾病
  • 神經系統疾病
  • 罕見疾病
  • 其他

7. 細胞和基因治療CDMO市場：區域估算和趨勢分析（按服務、型號和最終用途分類）

  • 市場概覽：按地區
  • 全球市場概覽：按地區分類
  • 市場規模預測及趨勢分析（2021-2033）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 阿曼
    • 卡達

第8章 競爭情勢

  • 公司分類
  • 細胞和基因治療CDMO市場佔有率分析（2024年）
  • 公司簡介
    • Lonza
    • Catalent, Inc
    • Cytiva
    • Samsung Biologics
    • Thermo Fisher Scientific Inc.
    • Novartis AG
    • WuXi AppTec
    • AGC Biologics
    • OmniaBio
    • Charles River Laboratories
    • Rentschler Biopharma SE
Product Code: GVR-4-68040-167-4

Cell And Gene Therapy CDMO Market Summary

The global cell and gene therapy CDMO market size was valued at USD 4.31 billion in 2024 and is projected to reach USD 27.12 billion by 2033, growing at a CAGR of 23.03% from 2025 to 2033. The industry is driven by the expanding portfolio of cell and gene therapy products, increased researcher attention on rare diseases, and substantial investments from both public and private sectors in research and development.

The rising demand for outsourced services related to cell and gene therapies, the increasing prevalence of chronic ailments such as cancer, a surge in mergers & acquisitions activities, and ongoing technological innovations throughout the cell and gene therapy development process are also fueling the growth. The market is primarily driven by the increased R&D funding and investments in cell and gene therapeutics (CGT) by the biotechnology and pharmaceutical industries. Cell and gene therapies hold significant potential in treating a wide range of diseases, including cancer, genetic disorders, and certain infectious diseases. Hence, owing to the great potential of these therapeutics, there has been a considerable increase in interest from both private and public sectors in the development and discovery of innovative cell and gene therapies. Most big pharmaceutical companies are now investing in CGT to create a strong position in the market. There has been a considerable increase in venture capital investments, especially in the life sciences sector.

Furthermore, an increased clinical pipeline and persistent reliance on outsourcing due to the specialized expertise and infrastructure required for production are also factors which is driving market growth. According to the data published by clinicaltrials.org there are currently over 2,000 ongoing clinical trials in cell and gene therapies that are progressing through development stages, and each transition from early to late phase amplifies the demand for viral vectors, plasmids, and clinical-grade cell processing. FDA approvals of novel treatments such as Casgevy for sickle cell disease and Elevidys for Duchenne muscular dystrophy in 2023-24, alongside EMA's approval of Roctavian for hemophilia A, highlight the growing momentum of advanced therapies entering the commercial stage. Most small and mid-sized biotech firms pioneering these innovations lack large-scale GMP facilities, making partnerships with CDMOs essential to reach patients. To meet this surge, leading players like Lonza, Catalent, WuXi Advanced Therapies, and Thermo Fisher have invested heavily in expanding viral vector and cell therapy capacity, indicating strong confidence in sustained outsourcing demand. Together, these drivers position the market for sustained high growth as approvals accelerate, pipelines deepen, and manufacturing needs outpace in-house capabilities.

Global Cell And Gene Therapy CDMO Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cell and gene therapy CDMO market report based on phase, product, indication, and region.

  • Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Pre-clinical
  • Clinical
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Gene Therapy
    • Ex-vivo
    • In-vivo
  • Gene-Modified Cell Therapy
    • CAR T-cell therapies
    • CAR-NK cell therapy
    • TCR-T cell therapy
    • Others
  • Cell Therapy
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Infectious Diseases
  • Neurological disorders
  • Rare Diseases
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Norway
    • Sweden
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Oman
    • Qatar

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Value chain based analysis (Model 2)
    • 1.7.3. Multivariate Analysis (Model 3)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cell And Gene Therapy CDMO Market: Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Cell And Gene Therapy CDMO Market Dynamics
    • 3.2.1. Market Driver Impact Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Technological Landscape
  • 3.4. Pricing Model Analysis
  • 3.5. Cell And Gene Therapy CDMO Market: Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. PESTEL Analysis

Chapter 4. Cell And Gene Therapy CDMO Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Cell And Gene Therapy CDMO Market Phase Movement Analysis
  • 4.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Phase, 2021 to 2033 (USD Million)
  • 4.4. Pre-clinical
    • 4.4.1. Pre-clinical Market Estimates and Forecasts, 2021 - 2033 (USD million)
  • 4.5. Clinical
    • 4.5.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cell And Gene Therapy CDMO Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Cell And Gene Therapy CDMO Market Product Type Movement Analysis
  • 5.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
  • 5.4. Gene Therapy
    • 5.4.1. Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.2. Ex-vivo
      • 5.4.2.1. Ex-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.4.3. In-vivo
      • 5.4.3.1. In-vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Gene-Modified Cell Therapy
    • 5.5.1. Gene-Modified Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.2. CAR T-cell therapies
      • 5.5.2.1. CAR T-cell therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.3. CAR-NK cell therapy
      • 5.5.3.1. CAR-NK cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.4. TCR-T cell therapy
      • 5.5.4.1. TCR-T cell therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.5.5. Other
      • 5.5.5.1. Other Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Cell Therapy
    • 5.6.1. Cell Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cell And Gene Therapy CDMO Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Cell And Gene Therapy CDMO Market Indication Movement Analysis
  • 6.3. Global Cell And Gene Therapy CDMO Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Infectious Diseases
    • 6.5.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Neurological disorders
    • 6.6.1. Neurological disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Rare Diseases
    • 6.7.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cell And Gene Therapy CDMO Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use

  • 7.1. Regional Market Dashboard
  • 7.2. Global Regional Market Snapshot
  • 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Competitive Scenario
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Competitive Scenario
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Competitive Scenario
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Competitive Scenario
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Competitive Scenario
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Competitive Scenario
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Competitive Scenario
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Competitive Scenario
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.6. Oman
      • 7.8.6.1. Key Country Dynamics
      • 7.8.6.2. Competitive Scenario
      • 7.8.6.3. Regulatory Framework
      • 7.8.6.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.7. Qatar
      • 7.8.7.1. Key Country Dynamics
      • 7.8.7.2. Competitive Scenario
      • 7.8.7.3. Regulatory Framework
      • 7.8.7.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Cell And Gene Therapy CDMO Market Share Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Lonza
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Catalent, Inc
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Cytiva
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Samsung Biologics
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Thermo Fisher Scientific Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Novartis AG
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. WuXi AppTec
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. AGC Biologics
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. OmniaBio
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Charles River Laboratories
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Rentschler Biopharma SE
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 4 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 5 North America Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 6 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 7 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 8 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 9 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 10 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 11 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 12 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 13 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 15 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 17 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 18 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 19 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 20 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 21 UK Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 22 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 23 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 24 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 25 France Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 26 France Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 27 France Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 28 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 29 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 30 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 31 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 32 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 33 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 34 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 35 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 36 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 37 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 38 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 39 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 40 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 41 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 42 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 47 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 48 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 49 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 50 China Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 51 China Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 52 China Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 53 India Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 54 India Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 55 India Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 56 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 57 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 58 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 59 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 60 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 61 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 62 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 63 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 64 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 65 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 67 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 68 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 69 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 70 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 71 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 72 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 73 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 74 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 75 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 77 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 78 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 79 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 80 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 81 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 85 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 86 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 87 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 88 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 89 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 90 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 91 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 92 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 93 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 94 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by phase, 2021 - 2033 (USD Million)
  • Table 95 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by product type, 2021 - 2033 (USD Million)
  • Table 96 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Cell And Gene Therapy CDMO Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Value-Chain-Based Sizing & Forecasting
  • Fig. 9 QFD model sizing & forecasting
  • Fig. 10 Bottom-up approach
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Segment snapshot
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Parent market outlook, 2024 (USD Million)
  • Fig. 17 Ancillary market outlook, 2024 (USD Million)
  • Fig. 18 Cell And Gene Therapy CDMO Market dynamics
  • Fig. 19 Total R&D drug pipeline size, 2021 - 2024
  • Fig. 20 Total drug pipeline by development phase, 2024
  • Fig. 21 Porter's five forces analysis
  • Fig. 22 PESTEL analysis
  • Fig. 23 Cell And Gene Therapy CDMO Market Phase outlook: Segment dashboard
  • Fig. 24 Cell And Gene Therapy CDMO Market, by Phase segment: Market share, 2025 & 2033
  • Fig. 25 Pre-clinical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Clinical market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Cell And Gene Therapy CDMO Market Product Type outlook: Segment dashboard
  • Fig. 28 Cell And Gene Therapy CDMO Market, by Product Type segment: Market share, 2025 & 2033
  • Fig. 29 Gene Therapy Gene-Modified Cell Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Ex-vivo market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 In-vivo market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Gene-Modified Cell Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 CAR T-cell therapies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 CAR-NK cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 TCR-T cell therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Cell Therapy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Cell And Gene Therapy CDMO Market Indication outlook: Segment dashboard
  • Fig. 39 Cell And Gene Therapy CDMO Market, by Indication segment: Market share, 2025 & 2033
  • Fig. 40 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Infectious Diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Neurological disorders market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Rare Diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Regional market: Key takeaways
  • Fig. 46 Regional marketplace: Key takeaways
  • Fig. 47 North America Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 U.S. Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Canada Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Mexico Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Europe Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 UK Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Germany Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Key country dynamics
  • Fig. 60 France Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Italy Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Spain Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 Denmark Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Norway Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Sweden Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Asia Pacific Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 Japan Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 China Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 India Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 Australia Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Korea Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Thailand Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Latin America Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Brazil Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Argentina Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 89 MEA Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 South Africa Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Key country dynamics
  • Fig. 93 Saudi Arabia Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Kuwait Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 UAE Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 Oman Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 100 Key country dynamics
  • Fig. 101 Qatar Cell And Gene Therapy CDMO Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 102 Market participant categorization
  • Fig. 103 Heat map analysis